Medical - Devices
Compare Stocks
4 / 10Stock Comparison
RXST vs ALGN vs TMDX vs HOLX
Revenue, margins, valuation, and 5-year total return — side by side.
Medical - Devices
Medical - Devices
Medical - Instruments & Supplies
RXST vs ALGN vs TMDX vs HOLX — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ||||
|---|---|---|---|---|
| Industry | Medical - Devices | Medical - Devices | Medical - Devices | Medical - Instruments & Supplies |
| Market Cap | $239M | $12.06B | $2.52B | $16.97B |
| Revenue (TTM) | $127M | $4.10B | $636M | $4.13B |
| Net Income (TTM) | $-47M | $430M | $172M | $544M |
| Gross Margin | 77.0% | 67.7% | 59.1% | 52.8% |
| Operating Margin | -43.4% | 14.4% | 14.9% | 17.5% |
| Forward P/E | — | 14.9x | 29.9x | 17.2x |
| Total Debt | $11M | $114M | $470M | $2.63B |
| Cash & Equiv. | $20M | $1.08B | $488M | $1.96B |
RXST vs ALGN vs TMDX vs HOLX — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Jul 21 | May 26 | Return |
|---|---|---|---|
| RxSight, Inc. (RXST) | 100 | 36.3 | -63.8% |
| Align Technology, I… (ALGN) | 100 | 24.2 | -75.8% |
| TransMedics Group, … (TMDX) | 100 | 255.6 | +155.6% |
| Hologic, Inc. (HOLX) | 100 | 100.7 | +0.7% |
Price return only. Dividends and distributions are not included.
Quick Verdict: RXST vs ALGN vs TMDX vs HOLX
Each card shows where this stock fits in a portfolio — not just who wins on paper.
RXST lags the leaders in this set but could rank higher in a more targeted comparison.
ALGN is the clearest fit if your priority is value.
- Lower P/E (14.9x vs 29.9x)
TMDX carries the broadest edge in this set and is the clearest fit for growth exposure and long-term compounding.
- Rev growth 37.1%, EPS growth 382.2%, 3Y rev CAGR 86.4%
- 226.0% 10Y total return vs HOLX's 124.3%
- 37.1% revenue growth vs RXST's -3.9%
- 27.0% margin vs RXST's -36.6%
HOLX is the #2 pick in this set and the best alternative if income & stability and sleep-well-at-night is your priority.
- beta 0.41
- Lower volatility, beta 0.41, Low D/E 52.0%, current ratio 3.75x
- Beta 0.41, current ratio 3.75x
- Beta 0.41 vs RXST's 1.73
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 37.1% revenue growth vs RXST's -3.9% | |
| Value | Lower P/E (14.9x vs 29.9x) | |
| Quality / Margins | 27.0% margin vs RXST's -36.6% | |
| Stability / Safety | Beta 0.41 vs RXST's 1.73 | |
| Dividends | Tie | None of these 4 stocks pay a meaningful dividend |
| Momentum (1Y) | +37.1% vs RXST's -61.1% | |
| Efficiency (ROA) | 15.8% ROA vs RXST's -15.1%, ROIC 18.8% vs -13.3% |
RXST vs ALGN vs TMDX vs HOLX — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
RXST vs ALGN vs TMDX vs HOLX — Financial Metrics
Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
RXST leads in 1 of 6 categories
ALGN leads 1 • TMDX leads 1 • HOLX leads 1 • 1 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
Evenly matched — TMDX and HOLX each lead in 2 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
HOLX is the larger business by revenue, generating $4.1B annually — 32.4x RXST's $127M. TMDX is the more profitable business, keeping 27.0% of every revenue dollar as net income compared to RXST's -36.6%. On growth, TMDX holds the edge at +21.2% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | ||||
|---|---|---|---|---|
| RevenueTrailing 12 months | $127M | $4.1B | $636M | $4.1B |
| EBITDAEarnings before interest/tax | -$57M | $790M | $115M | $974M |
| Net IncomeAfter-tax profit | -$47M | $430M | $172M | $544M |
| Free Cash FlowCash after capex | -$2M | $717M | $151M | $1000M |
| Gross MarginGross profit ÷ Revenue | +77.0% | +67.7% | +59.1% | +52.8% |
| Operating MarginEBIT ÷ Revenue | -43.4% | +14.4% | +14.9% | +17.5% |
| Net MarginNet income ÷ Revenue | -36.6% | +10.5% | +27.0% | +13.2% |
| FCF MarginFCF ÷ Revenue | -1.8% | +17.5% | +23.8% | +24.2% |
| Rev. Growth (YoY)Latest quarter vs prior year | -18.5% | +6.2% | +21.2% | +2.5% |
| EPS Growth (YoY)Latest quarter vs prior year | -90.0% | +23.6% | -71.4% | -9.2% |
Valuation Metrics
RXST leads this category, winning 3 of 6 comparable metrics.
Valuation Metrics
At 15.0x trailing earnings, TMDX trades at a 51% valuation discount to HOLX's 30.5x P/E. On an enterprise value basis, ALGN's 13.9x EV/EBITDA is more attractive than TMDX's 18.4x.
| Metric | ||||
|---|---|---|---|---|
| Market CapShares × price | $239M | $12.1B | $2.5B | $17.0B |
| Enterprise ValueMkt cap + debt − cash | $230M | $11.1B | $2.5B | $17.6B |
| Trailing P/EPrice ÷ TTM EPS | -6.11x | 29.80x | 14.97x | 30.53x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 14.85x | 29.86x | 17.21x |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | — |
| EV / EBITDAEnterprise value multiple | — | 13.92x | 18.42x | 17.39x |
| Price / SalesMarket cap ÷ Revenue | 1.78x | 2.99x | 4.16x | 4.14x |
| Price / BookPrice ÷ Book value/share | 0.87x | 3.02x | 6.25x | 3.43x |
| Price / FCFMarket cap ÷ FCF | — | 24.57x | 18.86x | 18.44x |
Profitability & Efficiency
ALGN leads this category, winning 5 of 9 comparable metrics.
Profitability & Efficiency
TMDX delivers a 41.9% return on equity — every $100 of shareholder capital generates $42 in annual profit, vs $-17 for RXST. ALGN carries lower financial leverage with a 0.03x debt-to-equity ratio, signaling a more conservative balance sheet compared to TMDX's 0.99x. On the Piotroski fundamental quality scale (0–9), ALGN scores 7/9 vs RXST's 3/9, reflecting strong financial health.
| Metric | ||||
|---|---|---|---|---|
| ROE (TTM)Return on equity | -17.0% | +10.7% | +41.9% | +11.0% |
| ROA (TTM)Return on assets | -15.1% | +6.9% | +15.8% | +6.1% |
| ROICReturn on invested capital | -13.3% | +15.4% | +18.8% | +9.4% |
| ROCEReturn on capital employed | -16.7% | +14.5% | +12.6% | +8.8% |
| Piotroski ScoreFundamental quality 0–9 | 3 | 7 | 7 | 7 |
| Debt / EquityFinancial leverage | 0.04x | 0.03x | 0.99x | 0.52x |
| Net DebtTotal debt minus cash | -$9M | -$965M | -$19M | $667M |
| Cash & Equiv.Liquid assets | $20M | $1.1B | $488M | $2.0B |
| Total DebtShort + long-term debt | $11M | $114M | $470M | $2.6B |
| Interest CoverageEBIT ÷ Interest expense | -4852.10x | 389.13x | 33.15x | 8.00x |
Total Returns (Dividends Reinvested)
TMDX leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in TMDX five years ago would be worth $30,074 today (with dividends reinvested), compared to $2,814 for ALGN. Over the past 12 months, HOLX leads with a +37.1% total return vs RXST's -61.1%. The 3-year compound annual growth rate (CAGR) favors TMDX at 0.9% vs RXST's -33.1% — a key indicator of consistent wealth creation.
| Metric | ||||
|---|---|---|---|---|
| YTD ReturnYear-to-date | -44.1% | +7.9% | -40.6% | +1.9% |
| 1-Year ReturnPast 12 months | -61.1% | -2.2% | -23.9% | +37.1% |
| 3-Year ReturnCumulative with dividends | -70.1% | -45.0% | +2.8% | -8.5% |
| 5-Year ReturnCumulative with dividends | -63.7% | -71.9% | +200.7% | +15.8% |
| 10-Year ReturnCumulative with dividends | -63.7% | +122.8% | +226.0% | +124.3% |
| CAGR (3Y)Annualised 3-year return | -33.1% | -18.1% | +0.9% | -2.9% |
Risk & Volatility
HOLX leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
HOLX is the less volatile stock with a 0.41 beta — it tends to amplify market swings less than RXST's 1.73 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. HOLX currently trades 100.0% from its 52-week high vs RXST's 34.6% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ||||
|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.73x | 1.66x | 1.59x | 0.41x |
| 52-Week HighHighest price in past year | $16.74 | $208.31 | $156.00 | $76.04 |
| 52-Week LowLowest price in past year | $5.30 | $122.00 | $70.00 | $52.81 |
| % of 52W HighCurrent price vs 52-week peak | +34.6% | +80.8% | +46.7% | +100.0% |
| RSI (14)Momentum oscillator 0–100 | 43.5 | 44.6 | 21.8 | 69.1 |
| Avg Volume (50D)Average daily shares traded | 741K | 1.1M | 1.1M | 10.0M |
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Analyst consensus: RXST as "Hold", ALGN as "Buy", TMDX as "Buy", HOLX as "Hold". Consensus price targets imply 98.6% upside for TMDX (target: $145) vs 3.9% for HOLX (target: $79).
| Metric | ||||
|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Hold | Buy | Buy | Hold |
| Price TargetConsensus 12-month target | $10.75 | $203.60 | $144.75 | $79.00 |
| # AnalystsCovering analysts | 12 | 33 | 12 | 42 |
| Dividend YieldAnnual dividend ÷ price | — | — | — | — |
| Dividend StreakConsecutive years of raises | — | — | — | — |
| Dividend / ShareAnnual DPS | — | — | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +3.9% | +0.0% | +4.4% |
RXST leads in 1 of 6 categories (Valuation Metrics). ALGN leads in 1 (Profitability & Efficiency). 1 tied.
RXST vs ALGN vs TMDX vs HOLX: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is RXST or ALGN or TMDX or HOLX a better buy right now?
For growth investors, TransMedics Group, Inc.
(TMDX) is the stronger pick with 37. 1% revenue growth year-over-year, versus -3. 9% for RxSight, Inc. (RXST). TransMedics Group, Inc. (TMDX) offers the better valuation at 15. 0x trailing P/E (29. 9x forward), making it the more compelling value choice. Analysts rate Align Technology, Inc. (ALGN) a "Buy" — based on 33 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — RXST or ALGN or TMDX or HOLX?
On trailing P/E, TransMedics Group, Inc.
(TMDX) is the cheapest at 15. 0x versus Hologic, Inc. at 30. 5x. On forward P/E, Align Technology, Inc. is actually cheaper at 14. 9x — notably different from the trailing picture, reflecting expected earnings growth.
03Which is the better long-term investment — RXST or ALGN or TMDX or HOLX?
Over the past 5 years, TransMedics Group, Inc.
(TMDX) delivered a total return of +200. 7%, compared to -71. 9% for Align Technology, Inc. (ALGN). Over 10 years, the gap is even starker: TMDX returned +226. 0% versus RXST's -63. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — RXST or ALGN or TMDX or HOLX?
By beta (market sensitivity over 5 years), Hologic, Inc.
(HOLX) is the lower-risk stock at 0. 41β versus RxSight, Inc. 's 1. 73β — meaning RXST is approximately 320% more volatile than HOLX relative to the S&P 500. On balance sheet safety, Align Technology, Inc. (ALGN) carries a lower debt/equity ratio of 3% versus 99% for TransMedics Group, Inc. — giving it more financial flexibility in a downturn.
05Which is growing faster — RXST or ALGN or TMDX or HOLX?
By revenue growth (latest reported year), TransMedics Group, Inc.
(TMDX) is pulling ahead at 37. 1% versus -3. 9% for RxSight, Inc. (RXST). On earnings-per-share growth, the picture is similar: TransMedics Group, Inc. grew EPS 382. 2% year-over-year, compared to -33. 8% for RxSight, Inc.. Over a 3-year CAGR, TMDX leads at 86. 4% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — RXST or ALGN or TMDX or HOLX?
TransMedics Group, Inc.
(TMDX) is the more profitable company, earning 31. 4% net margin versus -29. 0% for RxSight, Inc. — meaning it keeps 31. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: TMDX leads at 17. 9% versus -35. 8% for RXST. At the gross margin level — before operating expenses — RXST leads at 76. 6%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is RXST or ALGN or TMDX or HOLX more undervalued right now?
On forward earnings alone, Align Technology, Inc.
(ALGN) trades at 14. 9x forward P/E versus 29. 9x for TransMedics Group, Inc. — 15. 0x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for TMDX: 98. 6% to $144. 75.
08Which pays a better dividend — RXST or ALGN or TMDX or HOLX?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
09Is RXST or ALGN or TMDX or HOLX better for a retirement portfolio?
For long-horizon retirement investors, Hologic, Inc.
(HOLX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 41), +124. 3% 10Y return). RxSight, Inc. (RXST) carries a higher beta of 1. 73 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (HOLX: +124. 3%, RXST: -63. 7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between RXST and ALGN and TMDX and HOLX?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: RXST is a small-cap quality compounder stock; ALGN is a mid-cap quality compounder stock; TMDX is a small-cap high-growth stock; HOLX is a mid-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.